RARX - Ra Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
2.17B
Enterprise Value 3
898.25M
Trailing P/E
N/A
Forward P/E 1
-19.27
PEG Ratio (5 yr expected) 1
N/A
Price/Sales (ttm)
869.58
Price/Book (mrq)
11.28
Enterprise Value/Revenue 3
359.30
Enterprise Value/EBITDA 6
-12.04

Trading Information

Stock Price History

Beta (3Y Monthly) 1.35
52-Week Change 3178.94%
S&P500 52-Week Change 38.78%
52 Week High 347.08
52 Week Low 311.27
50-Day Moving Average 329.16
200-Day Moving Average 327.19

Share Statistics

Avg Vol (3 month) 31M
Avg Vol (10 day) 34.73M
Shares Outstanding 547.01M
Float 35.74M
% Held by Insiders 14.47%
% Held by Institutions 192.70%
Shares Short (Sep 30, 2019) 43.3M
Short Ratio (Sep 30, 2019) 47.66
Short % of Float (Sep 30, 2019) 412.82%
Short % of Shares Outstanding (Sep 30, 2019) 47.02%
Shares Short (prior month Aug 30, 2019) 42.61M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-3,058.96%

Management Effectiveness

Return on Assets (ttm)-32.43%
Return on Equity (ttm)-54.83%

Income Statement

Revenue (ttm)2.5M
Revenue Per Share (ttm)0.07
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)2.5M
EBITDA -74.59M
Net Income Avi to Common (ttm)-73.64M
Diluted EPS (ttm)-1.95
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)173.6M
Total Cash Per Share (mrq)3.69
Total Debt (mrq)4.86M
Total Debt/Equity (mrq)2.80
Current Ratio (mrq)15.30
Book Value Per Share (mrq)4.10

Cash Flow Statement

Operating Cash Flow (ttm)-62.29M
Levered Free Cash Flow (ttm)-37.27M